HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

De novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting zinc-finger protein as a new favorable neuroblastoma gene.

AbstractPURPOSE:
Neuroblastoma is a childhood cancer that exhibits either a favorable or an unfavorable phenotype. Favorable neuroblastoma genes (EPHB6, EFNB2, EFNB3, NTRK1, and CD44) are genes whose high-level expression predicts favorable neuroblastoma disease outcome. Accordingly, the forced expression of these genes or their reactivation by gene silencing inhibitors in unfavorable neuroblastoma cells results in suppression of tumor growth and metastases. This study was undertaken to design an experimental strategy to identify additional favorable neuroblastoma genes.
EXPERIMENTAL DESIGN:
Favorable neuroblastoma gene candidates were first identified by gene expression profiling analysis on IMR5 neuroblastoma cells treated with inhibitors of DNA methylation and histone deacetylase against the untreated control cells. Among the candidates, we focused on MIZ-1, which encodes a MYC-interacting zinc-finger protein, because it is known to enhance the expression of growth suppressive genes, such as CDKN1A.
RESULTS:
High-level MIZ-1 expression was associated with favorable disease outcome of neuroblastoma (P = 0.0048). Forced MIZ-1 expression suppressed in vitro growth of neuroblastoma cell lines. High MIZ-1 expression was correlated with the small-size neuroblastoma xenografts treated with gene silencing inhibitors or a glucocorticoid. In addition, forced MIZ-1 expression enhanced the expression of CD44 and EFNB2 in neuroblastoma cell lines in vitro. Furthermore, MIZ-1 expression was positively correlated with the expression of favorable neuroblastoma genes (EFNB2, EFNB3, EPHB6, and NTRK1) in the human neuroblastoma xenograft therapeutic models.
CONCLUSION:
MIZ-1 is a new favorable neuroblastoma gene, which may directly or indirectly regulate the expression of other favorable neuroblastoma genes.
AuthorsNaohiko Ikegaki, Takahiro Gotoh, Bing Kung, Justin S Riceberg, David Y Kim, Huaqing Zhao, Eric F Rappaport, Sakeenah L Hicks, Robert C Seeger, Xao X Tang
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 13 Issue 20 Pg. 6001-9 (Oct 15 2007) ISSN: 1078-0432 [Print] United States
PMID17947461 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Glucocorticoids
  • Kruppel-Like Transcription Factors
  • Proto-Oncogene Proteins c-myc
  • ZBTB17 protein, human
Topics
  • Animals
  • Cell Line, Tumor
  • Central Nervous System Neoplasms (genetics, metabolism)
  • Cyclin-Dependent Kinase Inhibitor p21 (metabolism)
  • Gene Expression Regulation, Neoplastic
  • Glucocorticoids (metabolism)
  • Humans
  • Kruppel-Like Transcription Factors (biosynthesis, physiology)
  • Mice
  • Models, Biological
  • Neoplasm Transplantation
  • Neuroblastoma (genetics, metabolism)
  • Proto-Oncogene Proteins c-myc (metabolism)
  • Treatment Outcome
  • Zinc Fingers

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: